share_log

Sharps Technology, Inc. Regains Compliance With Nasdaq Minimum Bid Price Requirement

Sharps Technology, Inc. Regains Compliance With Nasdaq Minimum Bid Price Requirement

Sharps科技公司重新符合纳斯达克最低买盘价格要求
Quiver Quantitative ·  11/18 08:13

Sharps Technology has regained Nasdaq compliance with a minimum bid price of $1.00 per share as of November 5, 2024.

Sharps科技已于2024年11月5日恢复了纳斯达克合规性,最低买盘价格为每股1.00美元。

Quiver AI Summary

Quiver AI 概要

Sharps Technology, Inc., a medical device and pharmaceutical packaging company, announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share as of November 5, 2024. The company received notification from Nasdaq on November 13, 2024. CEO Robert Hayes expressed satisfaction with this compliance, emphasizing its importance for the company's future and thanking shareholders for their support during a recent reverse stock split that facilitated this outcome. Sharps specializes in advanced syringe products and has a manufacturing facility in Hungary, while also partnering with Nephron Pharmaceuticals to enhance its U.S. manufacturing capabilities.

Sharps科技公司是一家医疗器械和药品包装公司,宣布其已于2024年11月5日恢复了与纳斯达克最低买盘价格要求每股1.00美元的合规性。该公司于2024年11月13日收到了纳斯达克的通知。首席执行官罗伯特·海耶斯对这一合规性表示满意,强调其对公司未来的重要性,并感谢股东在最近进行的反向股票拆分期间的支持,这一拆分促进了这一结果。Sharps专注于先进的注射器产品,并在匈牙利拥有一个制造设施,同时与Nephron药品公司合作,以增强其在美国的生产能力。

Potential Positives

潜在的积极因素

  • The company has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.
  • The CEO expressed strong optimism regarding the compliance with bid price, highlighting its importance for future opportunities for the company and its shareholders.
  • The press release acknowledges and thanks shareholders for their support during the reverse split, indicating strong investor relations and communication.
  • 该公司已恢复了与纳斯达克最低买盘价格要求的合规性,确保其继续在交易所上市。
  • 首席执行官对合规的买盘价格表示强烈乐观,强调其对公司及其股东未来机会的重要性。
  • 新闻稿承认并感谢股东在反向拆分期间的支持,这显示出强大的投资者关系和沟通。

Potential Negatives

潜在负面影响

  • The announcement of regaining compliance with Nasdaq's minimum bid price requirement implies that the company had previously struggled with maintaining its stock price, indicating potential underlying financial or operational weaknesses.
  • The mention of a reverse split suggests that the company resorted to this measure due to low share prices, which can be perceived negatively by investors and might signal a lack of investor confidence.
  • The extensive cautionary language regarding forward-looking statements raises concerns about the company's future performance and stability, highlighting uncertainties that could negatively affect investor sentiment.
  • 恢复符合纳斯达克最低买盘价格要求的公告暗示该公司之前在维持股价方面遇到困难,这表明可能存在潜在的财务或运营弱点。
  • 提到的反向拆股表明公司因为股价低而采取了这一措施,这可能会被投资者负面解读,并可能显示出缺乏投资者信心。
  • 关于前瞻性陈述的大量警示性语言引发了对公司未来表现和稳定性的担忧,突显出可能对投资者情绪产生负面影响的不确定性。

FAQ

FAQ

What recent compliance achievement has Sharps Technology announced?

Sharps Technology最近宣布了什么合规成就?

Sharps Technology announced that it has regained compliance with Nasdaq's minimum bid price requirement as of November 5, 2024.

Sharps Technology宣布,截至2024年11月5日,已恢复符合纳斯达克最低买盘价格要求。

Why is Nasdaq compliance important for Sharps Technology?

为什么纳斯达克合规对Sharps Technology重要?

Nazdaq compliance is crucial as it enhances the Company's market presence and offers better opportunities for shareholders.

纳斯达克合规至关重要,因为它提升了公司的市场存在感,并为股东提供了更好的机会。

What products does Sharps Technology specialize in?

Sharps Technology专注于哪些产品?

Sharps Technology specializes in patented, best-in-class smart-safety syringe products and pharmaceutical packaging solutions.

Sharps Technology专注于专利、行业领先的智能安全注射器产品和药品包装解决方案。

How did the reverse split help Sharps regain compliance?

反向拆股如何帮助Sharps重新获得合规性?

The reverse split supported the increase in share price, helping Sharps regain compliance with Nasdaq's listing requirements.

反向拆股支持了股价的上涨,帮助Sharps重新获得纳斯达克的上市要求合规性。

Where is Sharps Technology's manufacturing facility located?

Sharps Technology的制造设施位于哪里?

Sharps Technology has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its U.S. capacity.

Sharps Technology在匈牙利有一个制造设施,并与Nephron药品公司合作扩大在美国的产能。

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

免责声明:这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。


$STSS Hedge Fund Activity

$STSS对冲基金活动

We have seen 6 institutional investors add shares of $STSS stock to their portfolio, and 11 decrease their positions in their most recent quarter.

我们看到6家机构投资者在最近一个季度增加了$STSS股票的持仓,而11家则降低了他们的持仓。

Here are some of the largest recent moves:

以下是一些最近最大的交易动态:

  • ESSENTIAL PLANNING, LLC. removed 155,424 shares (-95.5%) from their portfolio in Q3 2024
  • ALPHACORE CAPITAL LLC added 84,548 shares (+2100.0%) to their portfolio in Q3 2024
  • COMPASS ION ADVISORS, LLC removed 54,546 shares (-95.5%) from their portfolio in Q3 2024
  • WALLEYE CAPITAL LLC removed 40,296 shares (-100.0%) from their portfolio in Q2 2024
  • GARDEN STATE INVESTMENT ADVISORY SERVICES LLC added 7,860 shares (+inf%) to their portfolio in Q3 2024
  • RENAISSANCE TECHNOLOGIES LLC added 6,221 shares (+inf%) to their portfolio in Q3 2024
  • HIGHTOWER ADVISORS, LLC removed 5,491 shares (-100.0%) from their portfolio in Q3 2024
  • ESSENTIAL PLANNING, LLC. 在2024年第三季度从其投资组合中移除了155,424股(-95.5%)。
  • ALPHACORE CAPITAL LLC 在2024年第三季度向其投资组合中新增了84,548股(+2100.0%)。
  • COMPASS ION ADVISORS, LLC 在2024年第三季度从其投资组合中移除了54,546股(-95.5%)。
  • WALLEYE CAPITAL LLC 在2024年第二季度从其投资组合中移除了40,296股(-100.0%)。
  • GARDEN STATE INVESTMENt ADVISORY SERVICES LLC 在2024年第三季度向其投资组合中新增了7,860股(+inf%)。
  • RENAISSANCE TECHNOLOGIES LLC 在2024年第三季度向其投资组合中新增了6,221股(+inf%)。
  • HIGHTOWER ADVISORS, LLC 在2024年第三季度从其投资组合中减持了5,491股(-100.0%)。

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

要追踪对冲基金的股票组合,请查看Quiver Quantitative的机构持股仪表板。

Full Release

全面发布



NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) --

Sharps Technology, Inc.

(NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market ("Nasdaq") that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.


纽约,2024年11月18日(环球新闻) --

Sharps Technology, Inc.

(纳斯达克: "STSS" 和 "STSSW")("Sharps")是一家创新的器械和药品包装公司,提供专利的优质注射器产品。公司今天宣布,2024年11月13日,纳斯达克证券市场("纳斯达克")通知公司,至2024年11月5日,公司已恢复符合纳斯达克证券市场继续上市的最低买盘价格要求,即每股1.00美元,该要求载于纳斯达克上市规则5550(a)(2)。



The Company's Chief Executive Officer Robert Hayes stated, "We are extremely pleased with our bid price compliance. We view our listing on Nasdaq to be extremely important to us as a Company as it offers the Company and its shareholders the best opportunity for the future. Further, we want to thank the shareholders for their support of the reverse split that supported Sharps regaining compliance."


公司首席执行官Robert Hayes表示,"我们对我们的竞价符合性非常满意。我们认为在纳斯达克上市对我们公司非常重要,因为这为公司及其股东提供了最佳的未来机会。此外,我们要感谢股东对支持Sharps恢复符合性的逆向拆分的支持。"




About Sharps Technology:



关于Sharps 科技:



Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For additional information, please visit



.


Sharps科技是一家创新的器械和药品包装公司,为医疗行业提供专利、最佳安全智能注射器产品。公司的产品线专注于提供超低废物能力,采用同时具备被动和主动安全特性的注射器科技。Sharps还提供采用专业共聚物科技设计的产品,以支持预填充注射器市场领域。公司在匈牙利设有制造设施,并与Nephron药品公司合作,以扩大其在美国的制造能力。欲了解更多信息,请访问



.




Forward-Looking Statements:



前瞻性声明:



This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," "poised" or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.


本新闻稿包含"前瞻性声明"。前瞻性声明反映了我们对未来事件的当前看法。在本新闻稿中使用时,“预期”、“相信”、“估计”、“预期”、“未来”、“打算”、“计划”、“准备”或这些术语的否定形式以及类似表达,它们与我们或我们的管理有关,可以确定前瞻性声明。此类声明包括但不限于本新闻稿中与我们的业务策略,未来经营业绩和流动性,以及资金资源展望相关的声明。前瞻性声明基于我们对我们的业务,经济和其他未来条件的当前期望和假设。由于前瞻性声明涉及未来,因此它们受到固有的不确定性,风险和难以预测的环境变化的影响。我们的实际结果可能与前瞻性声明所 contemplat的结果有实质性差异,它们既不是历史事实的陈述,也不是对未来业绩的保证。因此,我们警告您不要依赖任何这些前瞻性声明。可能导致实际结果与前瞻性声明中所述结果实质性差异的重要因素包括但不限于我们筹集资本以资助持续运营的能力;我们保护知识产权的能力;任何侵权诉讼或其他诉讼对我们带来的影响;与其他供应商和产品的竞争;我们开发和商业化产品和服务的能力;政府监管的变化;我们完成融资交易的能力;以及与我们行业有关的其他因素,我们的业务和经营业绩。实际结果可能与预期,相信,估计,预期,打算或计划的结果有重大差异。可能导致我们实际结果与预期不符的因素或事件可能会时不时出现,我们无法预测其中的所有因素。我们无法保证未来的结果,活动水平,业绩或成就。公司假设无义务更新任何前瞻性声明以反映本发布日期之后可能出现的任何事件或情况。




Investor Relations:

Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
Or 407-644-4256
STSS@redchip.com



投资者关系:

Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
或407-644-4256
STSS@redchip.com



声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发